Amylyx Pharmaceuticals annual operating expenses
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Operating Expenses Growth & History (AMLX)
Amylyx Pharmaceuticals's operating expenses was $153.3M for fiscal 2025.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $153.3M | −$248.8M | −61.88% |
| 2024 | 2024-12-31 | $402.1M | $60.1M | +17.58% |
| 2023 | 2023-12-31 | $342.0M | $118.4M | +52.96% |
| 2022 | 2022-12-31 | $223.6M | $140.6M | +169.45% |
| 2021 | 2021-12-31 | $83.0M | — | — |
Amylyx Pharmaceuticals quarterly operating expenses
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $45.7M | $2.8M | +6.62% |
| Q1 2026 | 2026-03-31 | $43.8M | $6.0M | +15.81% |
| Q4 2025 | 2025-12-31 | $36.6M | −$3.4M | −8.46% |
| Q3 2025 | 2025-09-30 | $36.0M | −$40.0M | −52.64% |
| Q2 2025 | 2025-06-30 | $42.9M | −$32.4M | −43.06% |
| Q1 2025 | 2025-03-31 | $37.8M | −$173.0M | −82.06% |
| Q4 2024 | 2024-12-31 | $40.0M | −$66.5M | −62.46% |
| Q3 2024 | 2024-09-30 | $76.1M | −$7.9M | −9.40% |
| Q2 2024 | 2024-06-30 | $75.3M | −$2.8M | −3.53% |
| Q1 2024 | 2024-03-31 | $210.8M | $137.3M | +186.84% |
| Q4 2023 | 2023-12-31 | $106.5M | $40.0M | +60.23% |
| Q3 2023 | 2023-09-30 | $84.0M | $28.9M | +52.61% |
| Q2 2023 | 2023-06-30 | $78.0M | $23.8M | +43.80% |
| Q1 2023 | 2023-03-31 | $73.5M | $25.7M | +53.68% |
| Q4 2022 | 2022-12-31 | $66.5M | $38.2M | +134.78% |
| Q3 2022 | 2022-09-30 | $55.0M | $31.8M | +137.15% |
| Q2 2022 | 2022-06-30 | $54.3M | $35.7M | +191.89% |
| Q1 2022 | 2022-03-31 | $47.8M | $34.9M | +271.57% |
| Q4 2021 | 2021-12-31 | $28.3M | — | — |
| Q3 2021 | 2021-09-30 | $23.2M | — | — |
| Q2 2021 | 2021-06-30 | $18.6M | — | — |
| Q1 2021 | 2021-03-31 | $12.9M | — | — |
Amylyx Pharmaceuticals operating expenses trends
Between the periods ended 2021-12-31 and 2025-12-31, Amylyx Pharmaceuticals's operating expenses increased from $83.0M to $153.3M, a change of $70.3M. The latest reported quarter, Q2 2026, shows $45.7M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals source filings ↗